Role of pemetrexed in non-small cell lung cancer

Cancer Investigation

Volumn 25, Issue 1, 2007, Pages 59-66

  Longo Sorbello, Giuseppe S A ^a,b   Chen, Bobin ^a,c   Budak Alpdogan, Tulin ^a   Bertino, Joseph R ^a,d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c FUDAN UNIVERSITY   (China)

^d NONE   (United States)

Author keywords

Non small cell lung cancer; Permetraxed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; RETROVIRUS VECTOR; THYMIDYLATE SYNTHASE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FOLIC ACID DEFICIENCY; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION COMPLICATION; LETHARGY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 33947238447     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601130748     Document Type: Review

References (50)

1. Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
2. Theti, D.S.; Jackman, A.L. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin. Cancer. Res. 2004, 10, 1080-1089.
3. Parker, N.; Turk, M.J.; Westrick, E.; Lewis, J.D.; Low, P.S.; Leamon, C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005, 338, 284-293.
4. Schultz, R.M.; Patel, V.F.; Worzalla, J.F.; Shih, C. Role of the thymidylate synthase in the antitumor activity of the multitargeted antifolate LY231514. Anticancer Research 1999, 19, 437-443.
5. Ouellet, D.; Periclou, A.P.; Johnson, R.D.; Woodworth, J.R.; Lalonde, R.L.; Population pharmacokinetics of pemetrexed disodium (Alimta) in patients with cancer. Cancer. Chemother. Pharmacol. 2000, 46, 227-234.
6. Teicher, B.A.; Chen, V.; Shih, C.; Menon, K.; Forler, P.A.; Phares, V.G.; Amsrud, T. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenograft. Clin. Cancer Res. 2000, 6, 1016-1023.
7. Britten, C.D.; Izbicka, E.; Hilsenbeck, S.; Lawrence, R.; Davidson, K.; Cerna, C.; Gomez, L.; Rowinsky, E.K.; Weitman, S.; Von Hoff, D.D. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 1999, 44, 105-110.
8. Teicher, B.A.; Alvarez, E.; Liu, P.; Lu, K.; Menon, K.; Dempsey, J.; Schultz, R.M. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin. Oncol. 1999, 26 (Suppl. 6), 55-56.
9. Tonkinson, J.L.; Worzalla, J.F.; Teng, C.H.; Mendelsohn, L.G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999, 59, 3671-3676.
10. Tesei, A.; Ricotti, L.; De Paola, F.; Amadori, D.; Frassinetti, G.L. In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin. Cancer Res. 2002, 8, 233-239.
11. Rauchwerger, D.R.; Firby, P.S.; Hedley, D.W.; Moore, M.J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000, 60, 6075-6079.
12. Giovannetti, E.; Mey, V.; Danesi, R.; Mosca, I.; Del Tacca. M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Cancer Res. 2004, 10, 2936-2943.
13. Giovannetti, E.; Mey, V.; Nannizzi, S.; Pasqualetti, G.; Marini, L.; Del Tacca, M.; Danesi, R. Cellular and pharmacogenetics foundation of Synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol. Pharmacol. 2005, 68, 110-118.
14. Niyikiza, C.; Baker, S.D.; Seitz, D.E.; et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002, 1, 545-552.
15. Bajetta, E.; Celio, L.; Buzzoni, R.; et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. 2003, 14, 1543-1548.
16. Bertino, J.R.; Banerjee, D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin. Cancer Res. 2003, 4, 1235-1239.
17. Farrugia, D.C.; Ford, H.E.; Cunningham, D.; et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin. Cancer Res. 2003, 9, 792-801.
18. Olopade, O.I.; Buchhagen D.L.; Malik, K.; et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 1993, 53 (10 Suppl), 2410-2415.
19. Rusthoven, J.J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999, 17, 1194-1199.
20. Clarke, S.J.; Abratt, R.; Goedhals, L.; Boyer, M.J.; Millward, M.J.; Ackland, S.P. Phase II trial of pemetrexed disodium (Alimta, (LY 231514) in chemotherapy-native patients with advanced non-small-cell lung cancer. Ann. Oncol. 2002, 13, 737-741.
21. Smit, E.F.; Mattson, K.; von Pawel, J.; Manegold, C.; Clarcke, S.; Postmus, P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann. Oncol. 2003, 14, 455-460.
22. Hanna, N.; Shepherd, F.A.; Fossella, F.V.; et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22, 1589-1597.
23. Cohen, M.H.; Johnson, J.R.; Wang, Y-C.; Sridara, R.; Pazdur, R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. The Oncologist 2005, 10, 363-368.
24. Adjei, A.A.; Erlichman, C.; Sloan, J.A.; et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumor. J. Clin. Oncol. 2000, 18, 1748-1757.
25. Thodtman, R.; Depenbrock, H.; Dumez, H.; Blatter, J.; Johnson, R.D.; van Oosterom, A.; Hanauske, A.R. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 1999, 17, 3009-3016.
26. Hughes, A.; Calvert, P.; Azzabi, A.; et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2002, 20, 3533-3544.
27. Missett, J.L.; Gamelin, E.; Campone, M.; Delaloge, S.; Latz, J.E.; Bozec, L.; Fumoleau, P. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann. Oncol. 2004, 15, 1123-1129.
28. Mackay, H.; Carmichael, J.; Roberts, J.; et al. Phase I study of pemetrexed in combination with docetaxel in patients with advanced solid malignancies. Proc Am. Soc. Clin. Oncol. 2002, 21, 77b.
29. Clarke, S.J.; Boyer, M.J.; Millward, M.; et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005, 49, 401-412.
30. Manegold, C.; Gatzemeier, U.; von Pawel J.; Pirker, R.; Malayeri, R.; Blatter, J.; Krejcy, K. Front-line treatment of advanced non small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann. Oncol. 2000, 11, 435-440.
31. Shepherd, F.A.; Dancey, J.; Arnold, A.; et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trial Group. Cancer 2001, 92, 595-600.
32. Zinner, R.G.; Fossella, F.V.; Gladish, G.W.; et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005, 104, 2449-2456.
33. Scagliotti, G.V.; Korstsik, C.; Dark, G.G.; et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin. Cancer Res. 2005, 11, 690-696.
34. Monnerat, C.; Le Chevalier, T.; Kelly, K.; et al. Phase II study of pemtrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 5439-5446.
35. Ma, C.X.; Nair, S.; Thomas, S.; et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 2005, 23, 5929-5937.
36. Kelly, K.; Crowley, J.; Bunn, P.A., Jr.; et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 2001, 19, 3210-3218.
37. Schiller, J.H.; Harrington, D.; Belani, C.P.; et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
38. Scagliotti, G.V.; De Marinis, F.; Rinaldi, M.; et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002, 20, 4285-4291.
39. Fossella, F.; Pereira, J.R.; von Pawel, J.; et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003, 21, 3016-3024.
40. Mao, L. Recent advances in the molecular diagnosis of lung cancer. Oncogene 2002, 21, 6960-6969.
41. Mitsudomi, T.; Steinberg, S.M.; Oie, H.K.; et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991, 51, 4999-5002.
42. Broermann, P.; Junker, K.; Brandt, B.H.; Heinecke, A.; Freitag, L.; Berdel, W.E.; Thomas, M. Trimodality treatment in stage III non-small cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 2002, 94, 2055-2062.
43. Khuri, F.R.; Lotan, R.; Kemp, B.L.; et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small cell lung cancer. J. Clin. Oncol. 2000, 18, 2798-2804.
44. Khuri, F.R.; Wu, H.; Lee, J.J.; et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7, 861-867.
45. Shih, J.Y.; Yang, S.C.; Hong, T.M.; et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J. Natl. Cancer Inst. 2001, 93, 1392-1400.
46. Yuan, A.; Yang, P.C.; Yu, C.J.; Chen, W.J.; Lin, F.Y.; Kuo, S.H.; Luh, K.T. Interleukin-8 messenger ribonuclein acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 2000, 162, 1957-1963.
47. Soria, J.C.; Moon, C.; Kemp, B.L.; et al. Lack of interleukin-10 could predict poor outcome in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2003, 9, 1785-1791.
48. Bepler, G.; Gautam, A.; McIntyre, L.M.; et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small cell lung cancer. J. Clin. Oncol. 2002, 20, 1353-1360.
49. Capiaux, G.M.; Budak-Alpdogan, T.; Alpdogan, O.; et al. Protection of hemopoietic stem cell from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Therapy 2004, 11, 767-773.
50. May, C.; Gunther, R.; McIvor, R.S. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995, 86, 2439-2448.